296 related articles for article (PubMed ID: 24704820)
1. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A
J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820
[TBL] [Abstract][Full Text] [Related]
2. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
[TBL] [Abstract][Full Text] [Related]
3. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
4. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
5. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
6. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
7. Development of an ELISA based bridging assay as a surrogate measure of ADCC.
Miller AS; Tejada ML; Gazzano-Santoro H
J Immunol Methods; 2012 Nov; 385(1-2):45-50. PubMed ID: 22914441
[TBL] [Abstract][Full Text] [Related]
8. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.
Schnueriger A; Grau R; Sondermann P; Schreitmueller T; Marti S; Zocher M
Mol Immunol; 2011 Jul; 48(12-13):1512-7. PubMed ID: 21570725
[TBL] [Abstract][Full Text] [Related]
9. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
[TBL] [Abstract][Full Text] [Related]
10. Thaw-and-use target cells pre-labeled with calcein AM for antibody-dependent cell-mediated cytotoxicity assays.
Chung S; Nguyen V; Lin YL; Kamen L; Song A
J Immunol Methods; 2017 Aug; 447():37-46. PubMed ID: 28434980
[TBL] [Abstract][Full Text] [Related]
11. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
12. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
13. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
16. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
Armour KL; Smith CS; Clark MR
J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
[TBL] [Abstract][Full Text] [Related]
17. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.
Kircheis R; Halanek N; Koller I; Jost W; Schuster M; Gorr G; Hajszan K; Nechansky A
MAbs; 2012; 4(4):532-41. PubMed ID: 22665069
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.
Loubeau M; Ahmad A; Toma E; Menezes J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):137-45. PubMed ID: 9390564
[TBL] [Abstract][Full Text] [Related]
19. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
[TBL] [Abstract][Full Text] [Related]
20. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]